UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

April 10, 2012

 

Date of Report (Date of earliest event reported)

 

ELITE PHARMACEUTICALS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   001-15697   22-3542636
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

 

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

 

 

(201) 750-2646

(Company’s telephone number, including area code)

 

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Item 8.01 Other Events

 

On April 11, 2012, Elite Pharmaceuticals, Inc. (the “Company”) issued a press release to announce that the initial shipment of phentermine HCI capsules 15 mg and 30 mg was made to TAGI Pharma, a wholly owned subsidiary of Precision Dose, triggering a milestone payment under the License, Manufacturing and Supply Agreement.

 

A copy of the press release is being finished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

 

Item 9.01 Financial Statements and Exhibits

 

a) Not applicable.

b) Not applicable.

c) Not applicable.

d) Exhibits

 

 

 Exhibit No.Exhibit
   
99.1Press Release dated April 11, 2012

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: April 11, 2012

 

  ELITE PHARMACEUTICALS, INC.
   
  By:  /s/ Chris Dick
    Name: Chris Dick
Title: President and Chief Operating Officer